PVI Symposium | 2023

CAS Today

Increased Relevance & Access Strategies
Watch Now

Solutions that Save Lives

Innovation that Inspires

CGuard™ Carotid Stent System

Sustained stroke prevention in CAS(1).
Bringing patient safety through permanent embolic protection with MicroNet™(2)

Stroke is the Second Biggest Cause of Death Globally(3).

The risk of embolism with conventional carotid stenting is significant as approximately 2/3 of neurovascular events (stroke, TIA) occur after the CAS procedure takes place(4).

CGuard™ Embolic Prevention System

CGuard™ brings to the world the only carotid stent platform with patented MicroNet™ mesh technology designed to reduce stroke during and after CAS
S-icon

Safety with MicroNet™

S-icon

Simplicity with SmartFit™

S-icon

Clinical Success

Our Technology
prevention_image
*Investigational device in the USA

Expert Testimonials

Hear from experienced leading physicians about the clinical and patient benefits of the CGuard EPS MicroNet™ in carotid stenting
Dr. Chris Metzger
Interventional Cardiologist

Ballad Health System CVA Heart & Vascular Institute Kingsport

TN | USA

Dr. Roberto Chiappa
Vascular Surgeon

Sandro Pertini Hospital

Rome | Italy

Fireside Chat Series with Leading Vascular Experts

Benefits

CGuard™ is designed to improve clinical outcomes and save lives by trapping and sealing thrombus and plaque against the vessel wall to prevent embolization
Minimally Invasive Procedure
Short Procedure Time
Improved clinical outcomes
SmartFit™ for ease & patient safety
image

Welcome to InspireMD

Solutions that Save Lives.
Innovation that Inspires.
InspireMD is dedicated to the development of advanced technologies such as MicroNet™, which aim to transform the future of vascular procedures to improve outcomes in revascularisation.
image
About InspireMD

News

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System